Breaking News Instant updates and real-time market news.

CELG

Celgene

$101.64

-2.63 (-2.52%)

, AGIO

Agios Pharmaceuticals

$53.26

-1.76 (-3.20%)

07:31
10/12/16
10/12
07:31
10/12/16
07:31

Celgene, Agios announce diagnostic collaborations with Abbott

Celgene (CELG) and Agios Pharmaceuticals (AGIO) announced each company has entered into collaboration agreements with Abbott (ABT) to develop and commercialize companion diagnostic tests on Abbott's m2000 RealTime System to identify isocitrate dehydrogenase, or IDH, mutations in acute myeloid leukemia patients. Celgene is currently developing enasidenib, an IDH2 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH2 mutation. Agios is developing AG-120, an IDH1 mutant inhibitor, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation.

CELG

Celgene

$101.64

-2.63 (-2.52%)

AGIO

Agios Pharmaceuticals

$53.26

-1.76 (-3.20%)

ABT

Abbott

$40.90

-2.34 (-5.41%)

  • 19

    Oct

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$101.64

-2.63 (-2.52%)

09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
09/16/16
RBCM
09/16/16
NO CHANGE
RBCM
Celgene shares can advance, says RBC Capital
RBC Capital analyst Michael Yee says that Celgene's stock "can grind higher" as investors eventually understand that the company's GED-0301 drug could potentially generate $1B in revenue. Yee says endoscopy data the company is expected to present next month on GED-0301 "isn't likely to be impressive." However, he thinks the data will "suggest that the drug is working," and he says that investor expectations are low, while the recent pullback in the shares has created an attractive entry point.
09/12/16
PIPR
09/12/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer says Celgene GED-0301 data 'vague'
Piper Jaffray analyst Joshua Schimmer says he remains skeptical on the profile of Celgene's GED-0301 for Crohn's disease. This morning's "vague press release doesn't help despite the company's expressed confidence," Schimmer tells investors in a research note. He notes that while GED-0301 is not a relevant driver of his investment thesis, the drug is important to sentiment overall. The analyst reiterates an Overweight rating on Celgene.
AGIO Agios Pharmaceuticals
$53.26

-1.76 (-3.20%)

06/13/16
JANY
06/13/16
NO CHANGE
Target $47
JANY
Neutral
Agios Pharmaceuticals price target lowered to $47 from $52 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay noted that the de novo Hb increase in 50% of patients in an ongoing Phase 2 study of AG-348 reported by Agios Pharmaceuticals was "robust and clinically meaningful," but added that the lack of mechanistic impact on 2,3 DPG and ATP is "perplexing" and the fact that little to no clinical impact in patients with low Hb was shown is "troubling." The analyst, who thinks the commercial opportunity for AG-348/519 at launch could be about 1,000 patients, translating to a commercial opportunity of $200M-$300M, keeps a Neutral rating on shares and lowered his fair value estimate on the stock to $47 from $52.
08/19/16
08/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aratana Therapeutics (PETX) assumed with a Buy at Jefferies. 2. Arbutus Biopharma (ABUS) initiated with an Outperform at William Blair. 3. Acceleron (XLRN) initiated with a Buy at BTIG. 4. Agios Pharmaceuticals (AGIO) initiated with a Neutral at BTIG. 5. Suncor (SU) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Agios Pharmaceuticals initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Agios Pharmaceuticals with a Neutral saying the company's rare genetic disease program will probably become the key value driver, but recommends waiting for more definitive efficacy signals to become more bullish.
06/13/16
06/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Agios Pharmaceuticals (AGIO) upgraded to Buy from Hold at Canaccord and upgraded to Overweight from Neutral at JPMorgan with Canaccord analyst John Newman raising his price target for the shares to $90 from $50 and JPMorgan analyst Anupam Rama raising his price target for the shares to $62 from $50. 2. Estee Lauder (EL) upgraded to Buy from Outperform at CLSA after analyst Caroline Levy had a meeting with CEO Fabrizio Freda and CFO Tracey Travis and came away impressed by their confidence in Estee's business outlook, despite secular pressure on U.S. department stores and a shift in travel patterns by emerging market consumers. 3. NVIDIA (NVDA) upgraded to Buy from Neutral at Nomura with the firm saying it expects the company to benefit from strong secular trends, including higher gaming ASPs, and a strong datacenter outlook. 4. Aptose Biosciences (APTO) upgraded to Buy from Neutral at Roth Capital with analyst Joseph Pantginis saying the company has made a "significant" addition to its pipeline, signing an agreement with CrystalGenomics for CG-806, an inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases. 5. Concho Resources (CXO) upgraded to Overweight from Equal Weight at Morgan Stanley with analysts led by Evan Calio citing a more constructive view on the long-term commodity outlook, raising long-term oil price assumption for Brent to $80 and upgraded the E&P industry view to Attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABT Abbott
$40.90

-2.34 (-5.41%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:09
12/04/16
12/04
15:09
12/04/16
15:09
Conference/Events
Juno Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$18.90

-0.3 (-1.56%)

15:04
12/04/16
12/04
15:04
12/04/16
15:04
Hot Stocks
Atara Biotherapeutics reports presentation of Phase 2 CMV-CTL data »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCI

Johnson Controls

$45.32

-0.41 (-0.90%)

15:03
12/04/16
12/04
15:03
12/04/16
15:03
Conference/Events
Johnson Controls to hold a meeting »

Strategic Review &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$297.19

1.41 (0.48%)

14:59
12/04/16
12/04
14:59
12/04/16
14:59
Hot Stocks
Biogen reports data presentations on hemophilia treatments Eloctate, Alprolix »

Biogen and Swedish Orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

14:58
12/04/16
12/04
14:58
12/04/16
14:58
Conference/Events
Genmab to hold data review meeting »

Management discusses data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

, GOOG

Alphabet

$750.50

2.58 (0.34%)

14:53
12/04/16
12/04
14:53
12/04/16
14:53
Hot Stocks
Alphabet subsidiary Verily launches utensil product »

Alphabet subsidiary…

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

KYN

Kayne Anderson

$19.52

0.07 (0.36%)

14:48
12/04/16
12/04
14:48
12/04/16
14:48
Hot Stocks
Kayne Anderson reports net assets $2.2B as of November 30 »

Reports net asset value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KED

Kayne Anderson

$19.29

0.03 (0.16%)

14:47
12/04/16
12/04
14:47
12/04/16
14:47
Hot Stocks
Kayne Anderson reports net assets $205M as of November 30 »

Reports net asset value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$36.23

-0.05 (-0.14%)

, BURBY

Burberry

$18.08

0.265 (1.49%)

14:37
12/04/16
12/04
14:37
12/04/16
14:37
Periodicals
Burberry rejected multiple approaches from Coach, FT says »

Burberry (BURBY) rejected…

COH

Coach

$36.23

-0.05 (-0.14%)

BURBY

Burberry

$18.08

0.265 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$2.22

0.03 (1.37%)

, AMP

Ameriprise

$113.47

-1.57 (-1.36%)

14:31
12/04/16
12/04
14:31
12/04/16
14:31
Periodicals
UniCredit to sell asset manager to Amundi for over EUR 3B, FT says »

UniCredit (UNCFF) is set…

UNCFF

UniCredit

$2.22

0.03 (1.37%)

AMP

Ameriprise

$113.47

-1.57 (-1.36%)

FIG

Fortress

$5.10

-0.1 (-1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RXN

Rexnord

$20.27

-0.72 (-3.43%)

14:09
12/04/16
12/04
14:09
12/04/16
14:09
Hot Stocks
Trump targets Rexnord over Mexico relocation plans, says 'no more' »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.61

-0.27 (-0.69%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

13:57
12/04/16
12/04
13:57
12/04/16
13:57
Periodicals
DirecTV NOW unlikely to make money, Barron's says »

AT&T's (T)…

T

AT&T

$38.61

-0.27 (-0.69%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

ARCH

Arch Coal

$79.32

1.6 (2.06%)

13:27
12/04/16
12/04
13:27
12/04/16
13:27
Periodicals
Arch Coal could gain 75%, Barron's says »

Arch Coal, which emerged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$101.50

-1.2 (-1.17%)

13:12
12/04/16
12/04
13:12
12/04/16
13:12
Periodicals
Deere could keep climbing, Barron's says »

Deere stock recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$9.81

0.28 (2.94%)

, GME

GameStop

$24.27

-0.37 (-1.50%)

12:57
12/04/16
12/04
12:57
12/04/16
12:57
Periodicals
Corporate tax cut can't save all retailers, Barron's says »

Though President-elect…

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

12:40
12/04/16
12/04
12:40
12/04/16
12:40
Periodicals
Callaway Golf investors should take profits, Barron's says »

It "looks like a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVC

Entravision

12:36
12/04/16
12/04
12:36
12/04/16
12:36
Periodicals
Entravision shares could reach $9, Barron's says »

Hispanic-focused…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GOOG

Alphabet

$750.50

2.58 (0.34%)

, GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

12:26
12/04/16
12/04
12:26
12/04/16
12:26
Periodicals
Barron's picks top ten stocks for 2017 »

Selecting its ten…

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

AAPL

Apple

$109.90

0.41 (0.37%)

C

Citi

$56.02

-1.25 (-2.18%)

DAL

Delta Air Lines

$48.31

0.54 (1.13%)

DTEGY

Deutsche Telekom

$15.65

0.14 (0.90%)

MRK

Merck

$61.13

0.37 (0.61%)

NVS

Novartis

$68.17

0.42 (0.62%)

TOL

Toll Brothers

$29.32

0.18 (0.62%)

UL

Unilever; also tag UN

$39.67

0.5 (1.28%)

UN

Unilever; also tag UL

$39.47

0.35 (0.89%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 15

    Jan

  • 26

    Jan

  • 08

    Mar

  • 13

    Mar

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.